Racial differences among kidney transplant recipients may impact the total daily tacrolimus
dose required to achieve therapeutic tacrolimus concentrations. Previous studies suggest …

Study Objective To determine the effect of tacrolimus trough concentrations on clinical
outcomes in kidney transplantation, while assessing if African‐American (AA) race modifies …

Abstract The number of African Americans (AAs) on the kidney waiting list is increasing in
the United States. Several studies showed that AAs are at higher risk for rejection and graft …

We have observed in clinical practice that Native Americans require lower dosages of
tacrolimus to attain similar target blood trough levels compared to whites after renal …

Abstract Study Objective This study investigated race and sex differences in tacrolimus
pharmacokinetics and pharmacodynamics in stable kidney transplant recipients. Design and …

Purpose The pharmacokinetics of both tacrolimus and mycophenolic acid in renal transplant
recipients on a corticosteroid-free regimen was evaluated. Methods Upon administration of …

Introduction One factor impacting tacrolimus interpatient variability is the presence of CYP
3A5 polymorphisms. Low tacrolimus concentration‐to‐dose ratios (CDR s), or rapid …

Tacrolimus pharmacokinetics vary due to single nucleotide polymorphisms (SNPs) in
metabolizing enzymes and membrane transporters that alter drug elimination. Clinically we …

Background. Results of a multicenter, randomized, clinical trial demonstrated that tacrolimus
was more effective than cyclosporine in preventing acute rejection in cadaveric renal …

WHEN tested in in vitro models of immunosuppres-sion, tacrolimus is 10 to 100 times more
potent than cyclosporine. Thus, corresponding doses on a mg/kg basis are much lower than …